Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.94 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.94 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HBB | P68871 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2990827 | 0.97 | MEN1 (1.00) | MEN1KMT2ALMNATP53TSHR | |
| SCHEMBL226273 | 0.97 | MEN1 (1.00) | MEN1KMT2ALMNATP53TSHR | |
| Phosphine SCHEMBL27652671 | 0.94 | MEN1 (0.94) | MEN1KMT2ALMNATP53TSHR | |
| SCHEMBL27834982 | 0.94 | MEN1 (0.94) | MEN1KMT2ALMNATP53TSHR | |
| Hydrochloric Acid SCHEMBL28047633 | 0.91 | MEN1 (0.88) | MEN1KMT2ALMNATP53TSHR | |
| SCHEMBL28125636 | 0.91 | MEN1 (0.88) | MEN1KMT2ALMNATP53TSHR | |
| Hydrochloric Acid SCHEMBL8950200 | 0.89 | MEN1 (0.75) | MEN1KMT2ALMNATP53TSHR | |
| Tert-Butylamine SCHEMBL9152840 | 0.87 | MEN1 (0.71) | MEN1KMT2ALMNATP53TSHR | |
| Hydrochloric Acid SCHEMBL9492390 | 0.82 | MEN1 (0.65) | MEN1KMT2ALMNATP53TSHR | |
| SCHEMBL8997704 | 0.82 | MEN1 (0.71) | MEN1KMT2ALMNATP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 313 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216531-A1 | CHITOSAN-CONTAINING NANOPARTICLES FOR DELIVERY OF POLYNUCLEOTIDES | VALORISATION RECH HSCM LIMITED PARTNERSHIP (CA) | 2024-07-04 | — | — | US | claimed |
| CN-113292440-A | Preparation method of N, N-diisopropylethylenediamine and preparation method of pramiperacetam monohydrate | 浙江朗华制药有限公司 | 2021-08-24 | — | — | CN | claimed |
| CN-112225626-A | High-nutrient organic fertilizer prepared from livestock and poultry manure | 安徽正基生态农业有限公司 | 2021-01-15 | — | — | CN | claimed |
| CN-106365243-B | Abandon a class type rainwater deep cycle purifier and purification process thereof | 徐州工程学院 | 2020-09-08 | — | — | CN | claimed |
| CN-104341333-B | A kind of preparation method of pramiracetam sulfate | BEIJING HUARUI DINGXIN TECHNOLOGY CO., LTD. (CN) | 2016-03-02 | — | — | CN | claimed |
| CN-104341333-A | Preparation method of Pramiracetam sulfate | BEIJING HRDX MEDICINAL TECHNOLOGIES CO LTD | 2015-02-11 | — | — | CN | claimed |
| CN-101058542-B | [2-(2-Diisopropylamino-ethylamino)-ethyl]-diisopropyl-amine, and synthetic method and use thereof | UNIV ZHEJIANG | 2010-10-06 | — | — | CN | claimed |
| CN-101058542-A | [2-(2-Diisopropylamino-ethylamino)-ethyl]-diisopropyl-amine, and synthetic method and use thereof | UNIV ZHEJIANG (CN) | 2007-10-24 | — | — | CN | claimed |
| US-12398097-B2 | WDR5-MYC inhibitors | VANDERBILT UNIVERSITY (US) | 2025-08-26 | — | — | US | disclosed |
| US-20240216531-A1 | CHITOSAN-CONTAINING NANOPARTICLES FOR DELIVERY OF POLYNUCLEOTIDES | VALORISATION RECH HSCM LIMITED PARTNERSHIP (CA) | 2024-07-04 | — | — | US | disclosed |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| CN-115991653-A | Preparation method of prazoracetam key intermediate N, N-diisopropyl ethylenediamine | 河南省三生药业有限公司 | 2023-04-21 | — | — | CN | disclosed |
| US-20220289673-A1 | WDR5-MYC INHIBITORS | VANDERBILT UNIVERSITY | 2022-09-15 | — | — | US | disclosed |
| US-11420963-B2 | Rebamipide prodrugs, preparation method and use thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2022-08-23 | — | — | US | disclosed |
| US-4144338-A | N-pyrimidinyl-N-dialkylaminoalkyl ureas | MERCK & CO., INC. (US) | 1979-03-13 | — | — | US | disclosed |
| US-4113951-A | ANTIARRHYTHMIA | DELALANDE S. A. (FR) | 1978-09-12 | — | — | US | disclosed |
| US-4105849-A | [(Substituted )phenyl]phenylmethyl-1-(dialkylaminoalkyl)piperidines | G. D. SEARLE & CO. (US) | 1978-08-08 | — | — | US | disclosed |
| US-4073917-A | Local anesthetics tertiary aminoalkoxyphenyl ethers | ASTRA LAKEMEDEL AKTIEBOLAG (SW) | 1978-02-14 | — | — | US | disclosed |
| US-4009201-A | PARTIALLY OR FULLY QUATERNIZED POLYAMINE ESTERS OF ACRYLIC ACIDS | ALCOLAC INC. (US) | 1977-02-22 | — | — | US | disclosed |
| US-3953602-A | DELAYED HYPERSENSITIVITY | RICHARDSON-MERRELL INC. (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289673-A1 | WDR5-MYC INHIBITORS | MYC, WDR5, MYCBP | MEN1 1279/4885KMT2A 186/4885LMNA 2680/4885 |
| US-20240216531-A1 | CHITOSAN-CONTAINING NANOPARTICLES FOR DELIVERY OF POLYNUCLEOTIDES | TLR3, PCNP, H1-3 | MEN1 1339/4885KMT2A 2581/4885LMNA 425/4885 |
| US-12398097-B2 | WDR5-MYC inhibitors | MYC, WDR5, MYCBP | MEN1 1279/4885KMT2A 186/4885LMNA 2680/4885 |
| US-11420963-B2 | Rebamipide prodrugs, preparation method and use thereof | SI, CYP2A7, MLN | MEN1 2774/4885KMT2A 4445/4885LMNA 4782/4885 |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | MEN1 1971/4885KMT2A 2880/4885LMNA 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.